(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Metastatic Colorectal Cancer.

Related Posts

STAT+: Anthos stroke drug appears safer than common blo...

Nov 13, 2023

IBI-343 by Innovent Biologics for Solid Tumor: Likeliho...

Jun 20, 2024

Eli Lilly achieving significant gains in obesity results

Jun 7, 2023